Literature DB >> 11064500

Osteonecrosis in HIV: a case-control study.

A N Scribner1, P V Troia-Cancio, B A Cox, D Marcantonio, F Hamid, P Keiser, M Levi, B Allen, K Murphy, R E Jones, D J Skiest.   

Abstract

BACKGROUND: Osteonecrosis (avascular necrosis) has been infrequently reported in HIV-infected patients. It is not known whether HIV itself is an independent risk factor for osteonecrosis.
METHODS: We identified 25 patients with osteonecrosis from 1984 to 1999 from a large county teaching hospital and two large practices in Dallas County that specialize in HIV-disease related therapy. A retrospective chart review was performed to evaluate potential risk factors for osteonecrosis. Each case was matched with two controls for HIV positive status and date of osteonecrosis diagnosis.
RESULTS: In the study, 22 of 25 (88%) case patients had at least one osteonecrosis risk factor compared with 24 of 50 (48%) controls, p =.003. The most common osteonecrosis risk factors were hyperlipidemia (32%), alcoholism (28%), pancreatitis (16%), corticosteroids (12%), and hypercoaguability (12%). Of the cases, 12% were idiopathic. Multiple joints were involved in 72% of cases. Four of the case patients compared with none of the controls received megesterol acetate before the diagnosis of osteonecrosis, p =.01. No significant differences were found between cases and controls with respect to liver function tests, testosterone levels, triglyceride levels, cholesterol levels, or CD4 cell counts. Saquinavir was independently associated with osteonecrosis, p <.05. However, no differences in overall use of protease inhibitors among cases and controls were noted: 79% versus 76%, respectively.
CONCLUSIONS: The increased incidence of osteonecrosis in HIV/AIDS may be due to an increased frequency of risk factors previously associated with osteonecrosis such as hyperlipidemia, corticosteroid use, alcohol abuse, and hypercoaguability. Use of protease inhibitors was not independently associated with osteonecrosis.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11064500     DOI: 10.1097/00042560-200009010-00003

Source DB:  PubMed          Journal:  J Acquir Immune Defic Syndr        ISSN: 1525-4135            Impact factor:   3.731


  24 in total

1.  Avascular necrosis in HIV.

Authors:  Puja Mehta; Mark Nelson; Alexander Brand; Fiona Boag
Journal:  Rheumatol Int       Date:  2011-09-22       Impact factor: 2.631

Review 2.  Antiphospholipid antibodies and infections.

Authors:  R A Asherson; R Cervera
Journal:  Ann Rheum Dis       Date:  2003-05       Impact factor: 19.103

3.  Avascular necrosis of the femoral head in HIV positive patients-an assessment of risk factors and early response to surgical treatment.

Authors:  L Chokotho; W J Harrison; N Lubega; N C Mkandawire
Journal:  Malawi Med J       Date:  2013-06       Impact factor: 0.875

Review 4.  Interactions between antiretroviral drugs and drugs used for the therapy of the metabolic complications encountered during HIV infection.

Authors:  Carl J Fichtenbaum; John G Gerber
Journal:  Clin Pharmacokinet       Date:  2002       Impact factor: 6.447

5.  Prevalence and incidence of diabetes in HIV-infected minority patients on protease inhibitors.

Authors:  Behrouz Salehian; Josephine Bilas; Mohsen Bazargan; Mohammad Abbasian
Journal:  J Natl Med Assoc       Date:  2005-08       Impact factor: 1.798

6.  SAS weekly rounds: avascular necrosis.

Authors:  Thomas W Hamilton; Susan M Goodman; Mark Figgie
Journal:  HSS J       Date:  2009-03-18

Review 7.  [Pain management in non-juvenile, aseptic osteonecrosis].

Authors:  M Jäger; A Werner; S Lentrodt; U Mödder; R Krauspe
Journal:  Schmerz       Date:  2004-12       Impact factor: 1.107

8.  Operations about hip in human immunodeficiency virus-positive patients.

Authors:  Jeong Joon Yoo; Sae Hyung Chun; Young Sam Kwon; Kyung-Hoi Koo; Kang Sup Yoon; Hee Joong Kim
Journal:  Clin Orthop Surg       Date:  2010-02-04

9.  Osteonecrosis of the femoral head in patients with type 1 human immunodeficiency virus infection: clinical analysis and review.

Authors:  Jean-Cyr Yombi; Bernard Vandercam; Dunja Wilmes; Jean-Emile Dubuc; Anne Vincent; Pierre-Louis Docquier
Journal:  Clin Rheumatol       Date:  2009-03-10       Impact factor: 2.980

Review 10.  Adverse effects of antiretroviral therapy for HIV infection.

Authors:  Valentina Montessori; Natasha Press; Marianne Harris; Linda Akagi; Julio S G Montaner
Journal:  CMAJ       Date:  2004-01-20       Impact factor: 8.262

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.